Recent Company News

• 04:05 AM ET Feb 12, 2026
  

  Adlai Nortye doses first patient in US for phase 1 trial of AN9025 for advanced or metastatic solid tumors harboring RAS mutations ($9.29, 0.00)

• 09:22 AM ET Feb 03, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 09:22 AM ET Feb 03, 2026
  

  StreetAccount Summary - US Syndicate recap for 03-Feb

• 08:41 AM ET Feb 03, 2026
  

  StreetAccount Summary - US Initial Syndicate recap for 03-Feb

• 08:28 AM ET Feb 03, 2026
  

  StreetAccount Summary - US Pre-market trading

• 07:08 AM ET Feb 03, 2026
  

  Adlai Nortye announces $140.0M private placement of ~21.5M ADSs priced at $6.50/ADS ($9.27, 0.00)

• 11:59 PM ET Jan 30, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 10:05 AM ET Jan 30, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (163 total)

• 05:27 PM ET Jan 29, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:51 AM ET Jan 29, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market